Medipal : Notice of Revision to Full-Year Results Forecast

October 31, 2016

MEDIPAL HOLDINGS CORPORATION

Representative: Shuichi Watanabe, Representative Director, President and CEO Code number: 7459 (1st Section, Tokyo Stock Exchange)

Contact: Mamoru Tsuchishio, Manager of Corporate Communications Department

Tel: [phone]

Notice of Revision to Full-Year Results Forecast

MEDIPAL HOLDINGS CORPORATION ("MEDIPAL") has revised its forecast of consolidated results for the fiscal year ending March 31, 2017 (April 1, 2016 to March 31, 2017), which was announced on May 16, 2016. Details are as follows.

1. Revision to the Forecast of Consolidated Results for the Fiscal Year Ending March 31, 2017 (April 1, 2016 to March 31, 2017)

   (Millions of yen unless otherwise stated)

   Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share (Yen)
   Previous forecast (A)	3,103,000	42,500	55,500	31,000	136.90
   Revised forecast (B)	3,090,000	40,000	53,500	30,500	134.69
   Amount of change (B-A)	(13,000)	(2,500)	(2,000)	(500)	―
   Percentage change (%)	(0.4)	(5.9)	(3.6)	(1.6)	―
   (Reference) Results for fiscal year ended March 31, 2016	3,028,187	42,283	55,140	30,771	135.89

2. Reason for the Revision

In the Prescription Pharmaceutical Wholesale Business, sales have weakened in a market environment that is more challenging than expected due to factors including National Health Insurance drug price reductions implemented on April 1, 2016 and tapering off of demand for new hepatitis C treatments. Selling prices have also been lower than initially projected.

On the other hand, in the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business, performance in the first six months of the period was strong, reflecting factors including strong sales of seasonal products, cultivation of business with retailers and manufacturers, and efforts to improve internal business processes. As a result, on October 28, 2016 MEDIPAL subsidiary PALTAC CORPORATION revised its forecast of results for the fiscal year.

Taking into account the conditions in the Prescription Pharmaceutical Wholesale Business and the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business, MEDIPAL has revised its previously announced forecasts of net sales and operating income for the full fiscal year.

Note: The above consolidated results forecast is based on information available as of the date of this announcement. Future events may cause actual results to differ from the forecast.

# # #